We retrospectively assessed 36 patients with advanced HCC who had received sorafenib...Two (5.6%) patients received everolimus after sorafenib failure. The TSC2-high patient (TSC2 H-score = 230) experienced a shorter PFS of 2.1 months compared with the TSC2-moderate patient (TSC2 H-score = 150), whose PFS was 5.8 months...The TSC2-moderate HCC patient with lung and brain metastasis experience stable disease after two cycles of everolimus treatment, whereas the TSC2-high HCC patient with lung metastasis experienced rapid progression of the lung metastasis.